Pamufetinib

N/A

Report date: 2023/02/03 16:50:22
NME

Base Information

Drug NamePamufetinib
Drug Alias NameTAS-115
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor inhibitors +[4] 
TargetsVascular endothelial growth factor receptor 2Hepatocyte growth factor receptorPlatelet-derived growth factor receptor +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaiho Pharmaceutical Co LtdOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOtsuka Holdings Co LtdTaiho Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A